Antiphospholipid antibodies, including anti-
activity. Although in vivo assays that allow assessment of the pathogenic procoagulant activity of patient autoantibodies have recently been developed, the complex nature of the mixed species prevented determination of the particular species responsible for in vivo thrombosis. We have generated two human IgG monoclonal ACA from an APS patient with recurrent thrombosis. Both bound to cardiolipin in the presence of 10% bovine serum, but not in its absence, and both were reactive against phosphatidic acid, but were nonreactive against purified human (8-2 glycoprotein 1, DNA, heparan sulfate, or four other test antigens. Both monoclonal autoantibodies lacked lupus anticoagulant activity and did not inhibit prothrombinase activity. Remarkably, one of the monoclonal antibodies has thrombogenic properties when tested in an in vivo mouse model. This finding provides the first direct evidence that a particular antiphospholipid antibody specificity may contribute to in vivo thrombosis.
Patients with systemic lupus erythematosus and recurrent thrombosis often have significant titers of a variety of anticardiolipin antibodies (ACA; particularly those of the IgG isotypes), as detected by solid phase immunoassay (1) (2) (3) (4) (5) . Since most ACA also bind to a few other negatively charged phospholipids, such as phosphatidic acid (PA) or phosphatidylserine (PS), they are generally referred to as antiphospholipid antibodies (APA) (6) . Consequently, the combined features of recurrent episodes of thrombosis and pregnancy loss in systemic lupus erythematosus patients with serum APA are termed the antiphospholipid syndrome (APS) (2) (3) (4) (5) . APS can be diagnosed in patients with no other identifiable autoimmune disorders as well and is referred to as "primary APS" (4-6). Paradoxically, many APS patients also have a serum factor that inhibits certain aspects of in vitro blood clotting and it is thus termed the "lupus anticoagulant" (LAC) (2) (3) (4) (5) 7) . Importantly, APS patients with LAC rarely have any bleeding problem.
There have been considerable differences in reports concerning the binding properties of APA and their role(s) in causing and/or sustaining thrombosis (8) (9) (10) . Some studies showed that the binding of ACA to cardiolipin (CL) was markedly enhanced by a plasma protein, (32 glycoprotein 1 (f32GP1), suggesting that ACA reacted with phospholipidf32GP1 complexes- (11) (12) (13) (14) (15) . In contrast, other laboratories reported that these antibodies bound f32GP1 alone (16) (17) (18) (19) (20) (21) (22) . However, some laboratories failed to detect similar direct anti-(32GP1 binding (15, 23) . These conflicting data may reflect the heterogeneity of APA present in individual patient sera and/or different sets of these autoantibodies in clinically diverse patient populations in different studies. Moreover, the inconsistent findings suggest that thrombotic events in a patient may be caused by more than one kind of APA and autoantibody-mediated mechanism and that thrombosis may be accounted for by different kinds of APA in different patients (4, 24) . In any case, the confounding data point to the critical need to obtain monoclonal IgG APA from seropositive APS patients with thrombosis and study each APA in terms of its in vitro binding properties, but much more importantly, study their thrombogenic potential in animals. Once a thrombogenic APA is identified, careful study of such monoclonal APA will allow delineation of the mechanisms by which APA produces thrombosis in vivo in humans.
It is well established that one of the criteria to define a pathogenic autoantibody is the ability of a suspected antibody to passively transfer the relevant clinical manifestation to a normal animal (25) . Recently, murine models that demonstrate that passively administered APA can induce fetal loss and thrombosis have been established (26) (27) (28) (29) (30) (1/40) , the patient has never manifested rash, arthralgias, arthritis, organic brain syndrome, or serologies suggestive of lupus. The antithrombin activity (determined by chromogenic assay kit, Organon Technika-Cappel) and plasma levels of proteins C and S (determined by Laurell rocket immunoelectrophoresis) were normal. No mutation at position 1691 of factor V that renders the protein resistant to proteolytic inactivation by activated protein C was found. The blood sample for the present study was obtained when the patient was 2 months into a pregnancy, which culminated in the full-term delivery of a normal newborn. Medications at the time of blood donation consisted of prednisone (5 mg Immunological Assays for IgG ACA. ACA was determined by ELISA as described in detail (31) . Briefly, a microtiter plate was precoated with CL (50 ,ug/ml in ethanol; Sigma) or ethanol alone (as background control) and then blocked with 10% bovine serum in PBS. Test samples were diluted 1:1 with PBS containing 10% bovine serum and added to wells in duplicate. After a 1.5-hr incubation at room temperature, the plates were washed with PBS. Bound human IgG was detected with enzyme-labeled goat anti-human IgG and enzyme substrates. Binding to the ethanol-treated wells was subtracted from binding to CL-coated wells (31) .
Subsequently, the mAbs were analyzed by ELISA for their reactivities with the following antigens: type VI collagen (Sigma), BSA, keyhole limpet hemocyanin, tetanus toxoid (Connaught Laboratories), and bovine thymus single-stranded DNA (ssDNA; Sigma). All antigens were used at 50 ,ug/ml to coat the ELISA plates. Detection of antibody activity against heparan sulfate was done by ELISA (34) . The plates precoated with 150 ,lI of protamine chloride (0.5 mg/ml) were coated overnight at room temperature with 100 ,lI of heparan sulfate (25 ,tg/ml) and blocked with gelatin.
To determine the fine specificity of mAbs, mAbs were analyzed by ELISA for their binding to various phospholipids, including PA, PS, phosphatidylcholine (PC), and (PE; Sigma). The Purified human prothrombin displayed a single 68-kDa band on an SDS/10% polyacrylamide gel. Coagulation proteins were stored in aliquots at -70°C and thawed immediately before use in the assay. Inhibition of the prothrombinase reaction was calculated as [1 - (thrombin activity in a test sample/thrombin activity in NH IgG)] x 100% and was considered to be significant when percentage inhibition was .15%.
In Vivo Experiments. The mouse model of thrombosis employed in this study has been described in detail (29) . Briefly, CD1 mice (25-30 g, 4-8 weeks old, Charles River Breeding Laboratories) were injected i.p. with 500 ,ug of the indicated IgG preparations at time 0 and 48 hr later, resulting in a serum level in recipient mice of >50 GPL. At 72 hr, each animal was anesthetized, and the right femoral vein was exposed, resulting in a 1 cm segment of vein free for manipulation and observation. The vein was pinched with a pressure of 1500 g/mm2 to introduce a standardized thrombogenic injury. Clot formation and dissolution in the transilluminated vein were monitored with a microscope equipped with a closed-circuit video system (including a color monitor and a recorder). Thrombus sizes (in square micrometers) were measured 1 min after each pinch by freezing the digitized image and tracing the outer margin of the thrombus; the times (in minutes) of formation (from appearance to maximum size) and disappearance (from maximum size to disappearance) of the thrombus were measured as well. The unpaired Student's t test was used to compare the means of thrombus sizes and times (formation, disappearance) among groups. (Fig. 1) , indicating that both mAbs were specific for CL.
RESULTS

Generation
To determine the fine specificity of these two mAbs, the culture supernatants were analyzed against four other phospholipids, including PA, PC, PE, and PS, in the presence of bovine serum (containing bovine 832GP1). As can be seen in Fig. 2 shown). The combined data showed that both mAbs were specific for the phospholipids PA and CL. When the isotypes and subclasses of these two mAbs were tested, both ACA IS1 and IS2 were IgGI, K.
To determine if cofactor was required in the binding of ACA IS1 and IS2 to CL, affinity purified mAbs free of f32GP1 were compared for their binding to CL in the presence or absence of bovine serum. As shown in Fig. 3 (11, 13, 36) .
ACA IS1 and IS2 were tested for their binding to f32GP1, according to the protocol of Roubey et al. (22) (35) . Each sample was measured three times, and the mean ± SD is given.
tNH plasma and a patient plasma with known LAC activity were provided in a commercial KCT test kit (Thromboscreen; Pacific Hemostasis, Ventura, CA).
1The mAbs (2 mg/ml) and NH IgG (6 mg/ml) were in TBS. §LAC activity is considered positive when the ratio of the clotting time of the testing IgG to that of NH IgG exceeds 1.2 (33).
in Fig. 4 , we detected substantial anti-f32GP1 antibodies in the serum of patient IS at 1:100 and 1:400 dilutions. However, under identical conditions, ACA IS1 and IS2 did not bind to 132GP1. In contrast, the same mAb-containing supernatants (at both neat and 1:4 dilution) displayed significant binding to CL plus bovine serum.
In Vitro Physiological Properties of ACA ISI and IS2. The mAbs were then analyzed for LAC activity by a modified KCT assay (33, 35) . As can be seen in Table 1 , neither ACA IS1 nor ACA IS2 displayed LAC activity, as measured by the KCT. One of the proposed mechanisms for the LAC activity of APA 
4:
The difference between the ACA-and the Neg Hu mAb-treated mice is highly significant (P s 0.02).
is that the antibody binds to phospholipids in the prothrombinase complex and thus inhibits the generation of thrombin in the final common pathway of blood coagulation (6, 37) . Accordingly, both mAbs were examined for their effects in inhibiting prothrombinase activity. Table 2 shows that the two present mAbs do not inhibit generation of thrombin in the presence of liposomes composed of PS and PC, and minimally inhibit thrombin generation in the presence of the liposomes composed of CL and PC. These data are consistent with our observation that both mAbs reacted strongly with CL but were unreactive with PC or PS. Thrombogenic Properties of Monoclonal ACA IS2. An animal model was used to determine the thrombogenic potential of the two mAbs (29) . An initial exploratory study indicated that passively administered IS2, but not IS1, was thrombogenic in the CD1 mouse when compared with polyclonal NH IgG (data not shown).
Subsequently, two more experiments were performed to confirm the thrombogenic potential of ACA IS2. In each experiment, groups of four mice were injected with either ACA IS2 or a control human monoclonal IgG without ACA activity. Five thrombi were induced per mouse; the five measurements for each variable in each mouse were averaged, and the results were used to calculate the mean ± SD for each group. As can be seen in Table 3 , experiment 1, thrombus sizes were significantly larger (3400 ± 1079 1Im2) in mice injected with ACA IS2 compared with the thrombi in control mice (354 ± 200 1Im2). In addition, highly significant delays in thrombus formation and disappearance times were observed with ACA IS2 as compared with the non-ACA control. Similar results were shown in experiment 2 (Table 3) , in which the thrombus size was significantly higher in mice with ACA IS2 injection (2404.7 ± 1079.5 gm2 versus 606.25 ± 342.7 tkm2), and the thrombus formation and disappearance times were longer.
DISCUSSION
We generated two monoclonal IgG ACA by transforming peripheral blood mononuclear cells from a primary APS patient with recurrent thrombosis and high titers of serum ACA. This patient has normal protein C and protein S levels, and shows no mutation on position 1691 of factor V that renders the protein resistant to proteolytic inactivation by activated protein C. Therefore, the thrombosis events in this APS patient are not due to abnormal protein C, protein S, or factor V. The last finding is consistent with a recent report that factor V Leiden mutation is not common in APS patients (39) .
Both mAbs were monospecific for phospholipids in the presence of bovine serum and both bound to negatively charged CL and PA, but not to PS, PC, PE, heparan sulfate, or DNA. Lack of DNA crossreactivity is usually seen with polyclonal APA antibodies (40) (41) (42) (11, 13, 36) . Based on a KCT assay, the mAbs did not possess any LAC activity. Hence, the mAbs described in this report have features similar to at least one subset of polyclonal APA from patients with the APS, in that they are specific for some negatively charged phospholipids, exhibit enhanced binding activity in the presence of sera, and lack LAC or prothrombinase inhibitory activity (11, (43) (44) (45) (46) .
During the course of our studies, Hasegawa et al. reported the generation of two monoclonal IgM ACA by transforming peripheral blood mononuclear cells from a 38-year-old woman with primary APS (47) . Of these two mAbs, one displayed LAC activity. Importantly, Hasegawa et al. did not study the potential in vivo prothrombotic properties of these monoclonals. Taken together with our findings, the properties of these four monoclonal ACA from two APS patients clearly indicate that generation and characterization of monoclonal ACA from patients are required to define various properties of specific individual APA in APS. Such monoclonal reagents may contribute to identification of disease-relevant thrombogenic autoantibodies.
Though lacking LAC activity, ACA IS2 is thrombogenic in an in vivo animal model. This is the first evidence demonstrating that an APS patient-derived monoclonal ACA can have thrombogenic properties. Several candidate mechanisms have been proposed to explain the thrombogenic properties of APA in APS patients (for reviews, see refs. 4, 10, and 24) . Certain APA may bind to f32GP1 and/or its complexes with phospholipid and, thus, interfere with proposed anticoagulant functions of f32GP1 and lead to a hypercoagulable state (11, 48, 49) . However, a main problem with this hypothesis is that the individuals homozygous for the null allele of f32GP1 are completely healthy (50) . Alternatively, APA may interfere with antithrombin activity through binding to heparin-like molecules (51, 52) . However, this mechanism may not explain the thrombogenic activity of-ACA IS2 since ACA IS2 does not bind heparan sulfate. Some APA may react with phospholipids on endothelial cells and, thus, reduce their production of prostacyclin (which inhibits platelet aggregation) and/or interfere with the thrombomodulin-dependent activation of protein C (4, 36, 53) . Since activated protein C proteolytically inactivates activated factors Va and Vllla, the reduced activation of protein C may lead to a procoagulant effect and thrombotic events. In addition, APA may bind to platelets and promote platelet aggregation (38, (55) (56) (57) .
The evidence from a single mAb does not establish that ACA in APS patients are thrombogenic, but it does support the hypothesis that this type of ACA in APS patients may be thrombogenic. The availability of the present patient-derived monoclonal thrombogenic ACA as well as the generation of additional monoclonal IgG APA will allow us to examine decisively all proposed mechanisms of APA-mediated thrombosis in vitro and in vivo. Moreover, the mAbs can be characterized at the molecular level, so that the structural bases of various binding patterns and biological functions may be delineated. 
